The introduction of an injectable GLP-1 has opened up new possibilities for patients with type 2 diabetes and obesity
Coverage is one of the most frustrating parts of GLP-1 care
We incorporated our genetic findings into broader models that combine demographic, clinical and genetic features to predict efficacy and side effects, and demonstrated the ability of this model to stratify patients by weight loss in a held out electronic health record (EHR) dataset
For purposes of this article, when I make reference to GLP-1 agonists and their risks I am really referring to any of the medications found inside this class which includes: These are the brand names of these medications so you also might know them as: Dulaglutide Exenatide Semaglutide Liraglutide Lixisenatide This isnt a full list but it hits all of the major and most popular brands and names
Serious symptoms like spreading redness, pus, or fever require medical attention
You can follow this calculation if the product does not have the nutritional information per serving